Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Tha...
Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and or...
New data presented on novel orally bioavailable p300-selective degraders showing significant anti-t...
These are the first in a series of presentations scheduled through the end of the year sharing adva...
Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Adviso...
SK Biopharmaceuticals CEO Donghoon Lee maps out its medium to long-term strategy at a press confere...
* 'Zero WiredTM' and 'Zero EarbudsTM' named 'Winners' in the healthcare category for outstanding ...
SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse i...
- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South...
SK Biopharmaceuticals aims to become a 'total healthcare solution provider' as it strengthens its d...
Cenobamate (ONTOZRY®), for the treatment of uncontrolled focal-onset seizures in adults, is now ava...
SK Biopharmaceuticals receives the '$100 million Export Tower' award, becoming the first Korean pha...
Poster session features a preliminary study result of potential seizure monitoring and detection fo...
Mr. Lee brings expertise in global new biz development to further strengthen SK Biopharmaceuticals ...
SK Biopharmaceuticals is recognized in the digital health category for two wearable devices –Zero G...
State-run financing to provide two-year support of Phase 1 research for oncology candidate, SKL2796...